DiaMedica Therapeutics Inc.: current liabilities
Current liabilities for DiaMedica Therapeutics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All DiaMedica Therapeutics Inc. financial histories
What this measure means
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
Exact concept: us-gaap:LiabilitiesCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 5,132,000 | USD | 2026-03-30 | 10-K · 0001437749-26-010342 |
| At date | 2024-12-31 | 5,390,000 | USD | 2026-03-30 | 10-K · 0001437749-26-010342 |
| At date | 2023-12-31 | 2,786,000 | USD | 2025-03-17 | 10-K · 0001437749-25-008018 |
| At date | 2022-12-31 | 2,168,000 | USD | 2024-03-19 | 10-K · 0001437749-24-008522 |
| At date | 2021-12-31 | 1,524,000 | USD | 2023-03-28 | 10-K · 0001437749-23-008189 |
| At date | 2020-12-31 | 2,028,000 | USD | 2022-03-14 | 10-K · 0001437749-22-006163 |
| At date | 2019-12-31 | 1,318,000 | USD | 2021-03-10 | 10-K · 0001437749-21-005541 |
| At date | 2018-12-31 | 1,296,000 | USD | 2020-03-23 | 10-K · 0001437749-20-005906 |
| At date | 2017-12-31 | 1,003,000 | USD | 2019-03-19 | 10-K · 0001437749-19-005272 |
Related financial histories
- DiaMedica Therapeutics Inc.: total assets
- DiaMedica Therapeutics Inc.: stockholders equity
- DiaMedica Therapeutics Inc.: cash and cash equivalents
- DiaMedica Therapeutics Inc.: net income or loss
- DiaMedica Therapeutics Inc.: operating cash flow
- DiaMedica Therapeutics Inc.: capital expenditure payments
- DiaMedica Therapeutics Inc.: financing cash flow
- DiaMedica Therapeutics Inc.: investing cash flow
- DiaMedica Therapeutics Inc.: retained earnings or deficit
- DiaMedica Therapeutics Inc.: basic weighted-average shares
- DiaMedica Therapeutics Inc.: basic earnings per share
- DiaMedica Therapeutics Inc.: income tax expense or benefit
- DiaMedica Therapeutics Inc.: net property, plant and equipment
- DiaMedica Therapeutics Inc.: share-based compensation expense
- DiaMedica Therapeutics Inc.: operating income or loss
- DiaMedica Therapeutics Inc.: current assets
- DiaMedica Therapeutics Inc.: current accounts payable
- DiaMedica Therapeutics Inc.: net current accounts receivable
- DiaMedica Therapeutics Inc.: operating expenses
- DiaMedica Therapeutics Inc.: research and development expense
Inspect the source
- Entity
- DiaMedica Therapeutics Inc. / CIK 0001401040
- Captured
- 2026-09-20T08:00:36.620Z
- SEC response SHA-256
adeb7e203518bec856c688b7ed41ae272e966272fe3607e0a7415e1ef09fc65b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001401040.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))